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A B S T R A C T
The Wnt/β-catenin signaling pathway is an evolutionarily conserved developmental signaling event that plays a
critical role in regulating tissue development and maintaining homeostasis, the dysregulation of which con-
tributes to various diseases. Natural products have been widely recognized as a treasure trove of novel drug
discovery for millennia, and many clinical drugs are derived from natural small molecules. Mounting evidence
has demonstrated that many natural small molecules could inhibit the Wnt/β-catenin pathway, while the eﬃ-
cacy of natural products remains to be determined. Therefore, this paper primarily reviews the targeting me-
chanism of natural small molecules for aberrant Wnt/β-catenin pathway that is intimately implicated in the
pathogenesis of myriad diseases, such as cancers, renal diseases, neurodegenerative diseases and bone disorders.
In addition, this review also highlights some natural products that have the potential to halt Wnt/β-catenin
pathway, especially for porcupine, the receptors of Wnt ligands, β-catenin and β-catenin-dependent proteins.
Additionally, a series of natural small molecules have shown good therapeutic eﬀects against mutations of the
Wnt/β-catenin pathway, which may dramatically facilitate the development of natural products in Wnt/β-ca-
tenin pathway intervention.
1. Introduction
The Wnt/β-catenin signaling pathway is an evolutionarily con-
served cellular signaling cascade that plays prominent roles in various
biological processes and the pathogenesis of numerous diseases, such as
the early embryonic development as well as organogenesis and adult
tissue homeostasis [1]. The Wnt/β-catenin pathway primarily consists
of the canonical Wnt/β-catenin signaling (β-catenin/T cell factor (TCF)-
dependent interaction) and non-canonical Wnt/β-catenin signaling (β-
catenin/TCF-independent interaction) [2]. Canonical Wnt/β-catenin
signaling includes Wnt ligand secretion, Wnt/receptors interaction, β-
catenin stabilization and translocation [3,4]. Although the Wnt/β-ca-
tenin pathway shows many beneﬁts, its dysregulation causes extensive
diseases, such as cancer, cardiovascular disease and renal disease [5–9].
Many biological antibodies and chemotherapeutic reagents targeting
the aberrant Wnt/β-catenin signaling have been developed, some of
which are in diﬀerent clinical trials [9–17]. However, side eﬀects and
resistance of biological antibodies as well as chemotherapeutic reagents
are frequently observed in clinical trials, which severely restrict their
use.
Natural products have been widely used for the treatment of various
cancers, cardiovascular diseases and renal diseases for many years
[18–20]. It was reported that 46% of drugs approved by food and drug
administration are derived from natural small molecules from 1981 to
2014 [21]. Reportedly, many natural small molecules from natural
products have many eﬀective pharmacological activities, including
anti-cancer, anti-bacterial, anti-ﬁbrotic and anti-oxidant activities,
which fueling considerable enthusiam for natural products as a source
of pharmaceutical exploitation [19,22–29]. As thus, we posited that
targeting the Wnt/β-catenin pathway with natural small molecules may
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be an eﬀective therapy for identifying promising drug candidates. In
this review, we primarily describe the Wnt/β-catenin signaling pathway
in the development of multiple diseases such as cancer, renal disease,
neurodegenerative disease and bone disorder. Additionally, the un-
derlying mechanisms of small natural products that regulate the Wnt/β-
catenin pathway are also highlighted.
2. The Wnt/β-catenin signaling pathway
2.1. Canonical Wnt pathway activation mechanism
In the absence of Wnts, (Fig. 1A), β-catenin in the cytoplasm is
phosphorylated by glycogen synthase kinase 3β (GSK3β) and casein
kinase 1 (CK1), both of which are parts of destruction complex that
includes adenomatous polyposis coli (APC), axis inhibition protein
(Axin) and β-transducin repeats containing protein (β-TrCP). In addi-
tion, phosphorylated β-catenin is ubiquitinated by β-TrCP and ulti-
mately degraded by the proteasome [30–33]. When Wnt is present in
the cytoplasm, (Fig. 1B), it will be lipidated by a special palmitoyl
transferase-porcupine [34], further modiﬁed by Wntless in the Golgi
and ﬁnally secreted by exocytosis [35,36]. Frizzled (FZD) receptors, the
principal receptors for Wnts, consist of seven-transmembrane proteins
and cysteine-rich domain (CRD) in the N-terminal [37,38]. Low-density
lipoprotein receptor-related proteins (LRPs), the co-receptors of FZDs,
are long single-pass transmembrane proteins. Wnt ligands bind to FZD
or the CRD to induce the dimerization of FZD and LRP5/6 [4,39], as
well as the phosphorylation of LRP5/6. Subsequently, phosphorylated
LRP5/6 recruit Axin to membrane, and the destruction complex takes
apart, which leads to the stabilization of β-catenin in cytoplasm [40].
After stabilization, β-catenin proteins translocate to the nucleus where
they interact with the TCF/lymphoid enhancing factor (LEF) and se-
quentially activate downstream gene expression [41].
2.2. Relevant proteins and receptors in the Wnt/β-catenin pathway
Except for the above-mentioned proteins, other proteins, such as
Wnt4, ring ﬁnger protein 43 (RNF43) [42], zinc and ring ﬁnger 3 [43],
serine/threonine kinases [44], cellular homologue of myelocytomatosis
viral oncogene (c-Myc), the cell cycle regulator D1 (cyclin D1) [45],
surviving, Mitogen-activated protein kinase 1 as well as CK1e and traf2-
and-nck-interacting kinase, have also been discovered to be closely
associated with the Wnt signaling pathway, while diﬀerent proteins
appear to play diﬀerent roles in biochemical signaling mechanisms.
Moreover, a series of receptors are also involved in the Wnt/β-catenin
pathway. Mitogen-activated protein kinase 1 [46], CK1e and traf2-and-
nck-interacting kinase play pivotal roles in the activation of the Wnt/β-
catenin pathway in β-catenin-dependent cancer cells. Inactivation of
Wnt4 is vital for reproductive development of female mice [47]. Fur-
thermore, Planutis et al. discovers that many transmembrane receptors,
such as FZD1, FZD2, LRP4, roof plate-speciﬁc spondin (R-Spondin) and
receptor-like tyrosine kinase/receptor tyrosine kinase-like orphan re-
ceptor 2 (ROR2), are also implicated in Wnt/β-catenin pathway [48].
However, all of corresponding signals output fully depend on the re-
lative aﬃnities between Wnt ligands and its receptors [49]. For in-
stance, Wnt5a stimulates the stabilization of β-catenin target proteins
by binding to FZD and LRP, while Wnt5a inhibits the β-catenin-de-
pendent pathway via combining with ROR2. In addition, ROR2/planar
cell polarity (PCP) autocrine signaling is activated when Wnt-8a binds
to ROR2 [50].
3. Wnt/β-catenin pathway, diseases, natural small molecules
3.1. Cancers
3.1.1. Colon cancer
Colon cancer has high morbidity and mortality, representing the
third leading cancer in men and the second leading cancer in women
globally, with 1.2 million new cases and 600 000 deaths per year [51].
Fig. 1. Inactivated and activated Wnt/β-catenin signaling. (A) Inactivated Wnt/β-catenin signals. The destruction complex in the cytoplasm mainly consists of CK1,
GSK3β, Axin, APC, protein phosphatase 2A, and β-TrCP. When Wnt is absent, CK1 and GSK3β phosphorylate β-catenin. The β-TrCP ubiquitinate phosphorylated β-
catenin, and the latter is ﬁnally degraded by the proteasome. β-TrCP is a protein included in F-box. SCF is a complex of Skp, Cullin and F-box. (B) Activated Wnt
signaling. In the presence of Wnts, Wnt proteins are lipidated by the porcupine in the endoplasmic reticulum, modiﬁed by Wntless in Golgi and ultimately transported
to the plasma membrane for secretion. The binding of lipidated Wnts leads to the formation of a receptor complex, FZD and LRP5/6, which promotes the recruitment
of Dishevelled to the receptor complex and the phosphorylation of LRP5/6. The Axin interacts with phosphorylated LRP5/6 and the destruction complex takes apart,
which protects β-catenin from degradation. Stabilized β-catenin subsequently binds TCF in the nucleus of cells to regulate target genes.
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A series of signaling pathways contribute to the pathogenesis of colon
cancer, such as TGF-β/phosphatidyl inositol 3 kinase/protein kinase B
(AKT), NF-κB and Wnt/β-catenin signaling cascade (Fig. 2), of which
the Wnt/β-catenin pathway is dedicated contributor of colon cancer
since the discovery of APC gene mutations [52]. Emerging studies have
shown that the APC/β-catenin interaction, APC dysfunction [53] and
RNF43 mutations [42,54] exacerbate aberrant Wnt signaling, leading to
colon cancer, providing additionally evidence to previous studies.
Moreover, R-Spondins and leucine-rich repeat containing G-protein
coupled receptors 4–6 modules equally activate the Wnt/β-catenin
pathway in various subtypes of colon cancer [43]. Reportedly, yes-as-
sociated protein and transcriptional co-activators with PDZ-binding
motifs leave from destruction complex and accumulate in the nucleus,
decreasing the survival of patients with colon cancer [55,56]. Fur-
thermore, forkhead box protein O 3a, a transcriptional co-activator of
β-catenin, interacts with β-catenin and simultaneously increases its
concentration in the nucleus, which promotes local or distant tumour
metastases and signiﬁcantly attenuates the survival of colon cancer
patients with stages 3 and 4 [57]. Interestingly, an Axin2 mutation has
been recognized as a predisposing factor to colon cancer [58].
Ursolic acid and corosolic acid are natural pentacyclic triterpenoids
from various plants, both of which have been clariﬁcated as antagonists
of the Wnt/β-catenin pathway in colon cancer cells. Intriguingly, a β-
hydroxyl group at C-3 and carboxyl group at C-17 in ursolic acid were
Fig. 2. Crosstalk between the Wnt/β-catenin pathway and TGF-β/Smad in renal ﬁbrosis, phosphatidyl inositol 3 kinase/AKT and NF-κB in colon cancer, and bone
morphogenetic protein 2/Smad in osteoporosis.
Table 1
The intervention eﬀect of natural small molecules targeting Wnt/β-catenin pathway in diseases.
Diseases Compound(s) Therapeutic mechanisms Reference(s)
Colon cancer Ursolic acid Downregulating β-catenin and TCF-dependent gene expression [59]
Corosolic acid
Toosendanin Inhibiting AKT/GSK3β/β-catenin pathway [60]
Triptonide Inhibiting Wnt/β-catenin pathway [61]
Silibinin Downregulating β-catenin and cyclin D 1 expression [63]
Quercetin Downregulating c-Myc and cyclin D1 expression [62]
Apigenin Inhibiting β-catenin/TCF/LEF pathway [64]
Berberine Downregulating β-catenin expression [65]
Tetrandrine Promoting β-catenin degradation and c-Myc downregulation [66]
Breast cancer Crocin Downregulating FZD7 mRNA expression [83]
Triptolide Inhibiting Wnt/β-catenin pathway [86]
Renal disease Poricoic acid (ZC, ZD, ZE, ZG and ZH) Inhibiting Wnt/β-catenin pathway [116,117]
25-O-methylalisol F Inhibiting Wnt/β-catenin pathway [123]
Parkinson’s disease Curcumin Inhibiting Wnt/β-catenin pathway [128]
Osteoporosis Harpagoside Upregulating β-catenin, cyclin D1 and c-Myc expression and downregulating Dkk1 expression [163]
Dioscin Inhibiting AKT/GSK3/β-catenin pathway [140]
Wedelolactone Upregulating phosphorylated GSK3β and Runx2 expression and enhancing β-catenin nuclear
translocation
[141]
Kirenol Upregulating β-catenin, LRP5, disheveled2, Runx2 and p-GSK3β expression [142]
Astragaloside I Upregulating β-catenin and Runx2 expression [143]
Icariin Upregulating Runx2 expression and enhancing β-catenin nuclear translocation [144]
Tricin Upregulating Wnt3a expression and downregulating GSK3β expression [146]
Rheumatoid arthritis Resveratrol Downregulating Wnt5a expression [154]
Epigallocat-echin-3-gallate Inhibiting Wnt/β-catenin pathway [155]
Hair growth Ginsenoside F2 Upregulating β-catenin and LEF-1 expression and downregulating Dkk1 expression [157]
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previously proven to be cytotoxic to human promyelocytic leukaemia
cells (HL-60), gastric cancer cells (BGC) and HeLa cells. Additionally, a
carboxyl group at position C-17 and methyl group at position C-19 in
ursolic acid were positively associated with β-catenin degradation and
resistance to β-catenin/TCF interaction in ursolic acid-treated human
colon cancer tissue 15 cells (HCT15) with APC mutation [59].
Fig. 3. Structures of natural small molecules from natural products.
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Terpenoids, toosendanin and triptonide, possess distinct anti-cancer
mechanisms. Toosendanin extracted from the fruits or bark of Melia
toosendan Sieb et Zucc subverts the AKT/GSK3β/β-catenin axis [60].
Triptonide in Tripterygium wilfordii Hook F. is identiﬁed as an inducer of
apoptosis in human colon cancer cells (SW480 and RKO) and prostate
cancer cell lines (PC3), which beneﬁtes from the suppression of trip-
tonide in the Wnt pathway via targeting the C-terminal transcription
domain of β-catenin or its nuclear co-factor instead of β-catenin
translocation and β-catenin/TCF4 interaction [61]. Silibinin is a
ﬂavonolignan extracted from the seeds of milk thistle [62], and
downregulated β-catenin as well as cyclin D 1 in polyps demonstrates
the mechanism of silibinin against colon cancer in APCmin/+ mice [63].
Expression of c-Myc and cyclin D tends to be decreased in cancer stem
cells and in HCT116 cells treated with quercetin, a ﬂavonoid compound
which is widely found in tea, berries, capers, onions, grapes and apples
[62]. The ﬂavonoid apigenin is widely found in fruits (orange, grapes
and apples) and vegetables (parsley and onions). Recently, it is reported
that apigenin could signiﬁcantly inhibit proliferation, migration and
invasion of colon cancer cells through suppressing activated β-catenin/
TCF/LEF signaling cascades in human embryonic kidney 293T cells
(HEK293 T) as well as SW480 cells. Moreover, apigenin also restrains β-
catenin nuclear translocation in HCT15 cells and SW480 cells activated
by LiCl in a concentration-dependent manner [64]. However, unlike
ursolic acid, berberine is an isoquinoline alkaline from Coptis chinensis
and demonstrates inhibitory eﬀect on the expression, instead of the
degradation of β-catenin in HCT116 cells [65]. Likewise, tetrandrine,
an alkaloid bis-benzylisoquinoline isolated from the dried root of Ste-
phania tetrandra S. Moore, confers resistance to proliferation and
apoptosis in colon cancer via downregulating IGF binding protein 5
expression, which promotes β-catenin degradation and downregulates
c-Myc expression in dimethylhydrazine- and dextran sodium sulphate-
induced colorectal cancer LoVo cells [66].
Curcumin is a phenolic compound extracted from the rhizome of
turmeric (Curcuma longa) that is usually used in Asia as an additive,
spice and pigment [67–72]. Curcumin treatment suppressed the growth
of colon cancer cells through retarding cell proliferation via inhibiting
the Wnt/β-catenin pathway rather than by promoting apoptosis in mice
[73]. Curcumin treatment also downregulated miR-130a expression,
while miR-130a overexpression abolished the anti-tumour activity of
curcumin [73].
3.1.2. Endometrial cancer
Endometrial cancer occurs in the endometrium in perimenopausal
and postmenopausal women. Emerging evidence indicates that cur-
cumin possesses chemopreventive properties against various cancers
[74–76]. It has been reported that curcumin treatment inhibits pro-
liferation and apoptosis of human endometrial carcinoma cells by
downregulating expression of the androgen receptor and β-catenin in a
concentration- and time-dependent manner [77]. Wnt3a partially nul-
liﬁes the eﬀects of curcumin on proliferation and apoptosis in human
endometrial carcinoma cells, as well as the androgen receptor expres-
sion-downregulating eﬀect of curcumin [77]. These ﬁndings conﬁrm
that curcumin might inhibit diﬀerent cancers by repressing the Wnt/β-
catenin pathway via miR-130a. Hence, the Wnt/β-catenin pathway may
represent a new target of curcumin in cancer treatment.
3.1.3. Triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the most metastatic subtype
of breast cancer and cannot be overcome by standard therapy.
Oestrogen receptor, progesterone receptor and human epidermal
growth factor receptor-2 are three major subtypes of breast cancer [78].
Wnt signaling is widely accepted as one of the most common sources for
pro-proliferation signaling in TNBC cells, and the FZD7 protein may
represent a novel target or biomarker for TNBC treatment [79].
XAV939 and clofazimine have been identiﬁed as Wnt inhibitors and
promising anti-TNBC drugs, but neither of them have yet been used in
advanced clinical trials [80,81]. Fortunately, tannins, isolated from
Syzygium guineense, directly inactivates the stabilization and transcrip-
tion of Wnt3a-induced β-catenin expression, which may be pursued for
novel therapies [82]. As the most potent anti-cancer carotenoids in
saﬀron, crocin exhibits a more potent anti-metastatic ability on TNBC
through downregulating FZD7 mRNA expression and upregulating E-
cadherin expression in the Wnt/β-catenin pathway [83]. In contrast to
crocin, crocetin fails to impart its eﬀects on the Wnt/β-catenin pathway
[84]. Proanthocyanidins, isolated from Chinese bayberry leaf, attenuate
expression of β-catenin, cyclin D1 as well as c-Myc, and block the G1
cell cycle as well as self-renewal ability in ovarian cancer stem cells
(OVCAR-3 SP) [85]. Additionally, triptolide, isolated from Tripterygium
wilfordii Hook F., has an inhibitory eﬀect on myriad cancers, such as
liver cancer, non-small cell lung carcinoma, osteosarcoma, pancreatic
cancer as well as breast cancer, and has the capacity to remodel the
activated Wnt/β-catenin pathway [86]. Taken together, natural pro-
ducts play an important role in various cancer interventions by reg-
ulating the Wnt/β-catenin pathway and Wnt/β-catenin signaling may
represent a speciﬁc therapeutic target of natural small molecules
against cancers.
3.2. Renal disease and ﬁbrosis
Chronic kidney disease (CKD) is an epidemic that has increased by
73% from 1990 to 2013 and represents a primary cause of death
worldwide. Renal ﬁbrosis, characterized by tubulointerstitial ﬁbrosis
and glomerulosclerosis, is an inevitable outcome and ﬁnal manifesta-
tion of all kinds of progressive CKD [87–91]. Renal ﬁbrosis is closely
associated with mounting mediators and signaling pathways, such as
oxidative stress, inﬂammation, microRNAs, transforming growth factor
β1 (TGF-β1)/Smad and Wnt/β-catenin (Fig. 2), as well as the dysre-
gulated uremic toxins, amino acids and lipid metabolism [92–100]. In
recent decades, natural small molecules have gradually become an
important therapeutic strategy for the prevention and treatment of
renal ﬁbrosis worldwide [22,101,102]. Emerging studies suggest that
small molecular compounds isolated from natural products exert good
therapeutic eﬀects on renal disease and ﬁbrosis [103–106]. A number
of traditional Chinese medicines, such as Poria cocos (PC), Alismatis
rhizoma and Polyporus umbellatus, promote urination and eliminate
oedema, both of which are associated with the retardation of renal
disease and ﬁbrosis.
PC grows around the roots of pine trees in Asia and North America
[107]. PC and its surface layer have diuretic eﬀects [108,109], anti-
hyperlipidemic activity [110,111] and CKD treatment potential
[112–115]. Our study reported that poricoic acid ZG and poricoic acid
ZH, isolated from the surface layer of PC, signiﬁcantly ameliorated the
upregulated expression of Wnt1 and β-catenin, as well as its target gene
expression, including Snail1, Twist, matrix metalloproteinase 7, plas-
minogen activator inhibitor 1 and ﬁbroblast speciﬁc protein 1 in TGF-
β1-induced human kidney proximal epithelial cells (HK-2). Interest-
ingly, poricoic acid ZG and poricoic acid ZH also selectively suppressed
Smad3 phosphorylation through alleviating the interactions of smad
anchor for receptor activation with TGF-β receptor I and Smad3 in the
TGF-β/Smad pathway. Structure-function analysis indicated that the
antiﬁbrotic eﬀect was associated with the ﬁrst six-membered ring
structure and the number of carboxyl groups in tetracyclic triterpenoid
compounds [116]. In addition, we also obtained three new triterpe-
noids, including poricoic acid ZC, poricoic acid ZD and poricoic acid ZE,
and discovered that they could signiﬁcantly alleviate extracellular
matrix production by suppressing the Wnt/β-catenin pathway and
speciﬁc Smad3 phosphorylation via blocking the interaction of TGF-β
receptor I with Smad3 signaling in TGF-β1 or angiotensin II-induced
HK-2 cells and unilateral ureteral obstructive mice [117]. Structure-
activity analysis suggested that secolanostane tetracyclic triterpenoid
compounds, poricoic acid ZC and poricoic acid ZD, showed a stronger
inhibitory eﬀect than lanostane tetracyclic triterpenoid compound
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poricoic acid ZE, indicating that compounds with a secolanostance
skeleton exhibit stronger bioactivity than those with a lanostance ske-
leton.
Alismatis rhizome, the dried stem tuber of Alisma orientale (Sam.)
Juzep., exerts powerful diuretic, anti-hyperlipidemic eﬀects, which may
be intimately associated with the anti-ﬁbrotic eﬀect. [118–122]. Tri-
terpenoid compounds are the primary active components in Alismatis
rhizome [118,123]. 25-O-methylalisol F is a new tetracyclic triterpenoid
compound isolated from the Alismatis rhizome. Our latest study ﬁnd that
25-O-methylalisol F inhibits upregulated expression of Wnt1 as well as
β-catenin and its target gene expression, including Snail1, Twist, matrix
metalloproteinase-7, plasminogen activator inhibitor 1 and ﬁbroblast
speciﬁc protein 1, in both TGF-β1-induced HK-2 cells and normal rat
kidney interstitial ﬁbroblast cells (NRK-49 F). In addition, 25-O-me-
thylalisol F inhibits Smad3 phosphorylation and maintains Smad7 ex-
pression in the TGF-β/Smad-dependent pathway, exerting a strong in-
hibitory eﬀect on crosstalk between Wnt/β-catenin and TGF-β/Smad
pathways in the extracellular matrix [123]. Collectively, the Wnt/β-
catenin pathway may be a speciﬁc therapeutic target of natural small
molecules against renal ﬁbrosis.
3.3. Neurodegenerative diseases
Parkinson’s disease is the second most common neurodegenerative
disease, aﬀecting approximately 1% of the population aged 65 or older
worldwide [124]. Emerging management of Parkinson’s disease has
primarily focused on inhibitor medications, such as levodopa, dopa-
mine agonists, monoamine oxidase type B and catechol O-
methyltransferase inhibitors. In addition, surgery, rehabilitation and
palliative care are used for Parkinson’s disease treatment as well [125].
The causes of Parkinson’s disease are attributed to age, low serum urate
concentrations, smoking, α-synuclein mutations, leucine-rich repeat
kinase 2, phosphatase, tension homolog-induced putative kinase 1,
parkin 7, vacuolar protein sorting 35, receptor-mediated endocytosis 8
as well as coiled-coil-helix-coiled-coiled-helix domain containing 2
[124] and eukaryotic translation initiation factor 4-γ [126]. In addition,
leucine-rich repeat kinase 2 mutations also exacerbate disease pro-
gression by activating the Wnt/β-catenin pathway in adult mice and
cultured ﬁbroblasts [127]. It has been reported that curcumin isolated
from the rhizome of turmeric (Curcuma longa) exhibits neuro-protective
eﬀects and attenuates bisphenol A (BPA)-induced neurotoxicity through
inhibiting activated Wnt/β-catenin signaling, veriﬁed by the use of Wnt
speciﬁc activators, such as LiCl, GSK3β siRNA and inhibitor dickkopf
(Dkk) 1. Curcumin treatment signiﬁcantly reverses BPA-mediated in-
creased β-catenin phosphorylation, downregulated GSK3β expression
and β-catenin nuclear translocation in neural stem cells [128]. Mean-
while, neurogenesis as well as learning and memory in BPA-treated rats
were improved in response to curcumin [128]. These data indicate that
curcumin exhibits neuroprotection against BPA-mediated impaired
neurogenesis through depressing activated Wnt/β-catenin signaling.
Neurogenesis, the process of generating new neurons, is reduced in
several neurodegenerative disorders including Alzheimer's disease. It
has been reported that curcumin nanoparticles improve neuronal dif-
ferentiation via decreasing the expression of GSK3β, with enhanced β-
catenin nuclear translocation and promoter activity of the TCF/LEF and
cyclin D1 [129]. Treatment with curcumin nanoparticles further re-
verses learning and memory impairments by inducing neurogenesis in
an amyloid β-induced rat model of Alzheimer's disease [129]. More-
over, molecular docking studies indicates that curcumin interacts with
Wif-1, Dkk, and GSK3β. Collectively, these ﬁndings demonstrate that
curcumin treatment induces adult neurogenesis via activating the Wnt/
β-catenin pathway and improving the brain’s self-repair mechanisms,
which might represent a therapeutic intervention for neurodegenera-
tive diseases, such as Parkinson’s and Alzheimer's. Therefore, the Wnt/
β-catenin pathway may be exploited for a speciﬁc therapeutic target of
natural small molecules in the treatment of neurodegenerative disease.
3.4. Bone disorders
The balance between osteoblasts and osteoclasts plays signiﬁcant
roles in bone formation and maintenance, the loss of which results in
bone disorders, including osteoporosis [130]. As an age-dependent
metabolic bone disorder, osteoporosis has two main characteristics, low
bone mass and micro-architectural deterioration of bone tissue [131].
Unfortunately, current therapeutic strategies for osteoporosis are
mainly focused on physical exercise and medications, such as bispho-
sphonates, teriparatide, strontium ranelate and denosumab [132]. Ex-
cept for the pathogenic factors, the occurrence of osteoporosis is at-
tributed to both non-modiﬁable risk factors, such as gender, race,
heredity, age, and modiﬁable risk factors, such as medical disorders,
hypogonadal states, endocrine disorders, vitamin D deﬁciency and
long-term intake of proton pump inhibitors [133,134]. Emerging evi-
dence suggests that bone morphogenetic protein 2/Smad and Wnt/β-
catenin pathways (Fig. 2) are associated with osteoporosis [135–137].
Enhanced β-catenin phosphorylation and GSK3β in senile osteoporosis
indicate that the Wnt/β-catenin pathway is a possible therapeutic target
in the treatment of osteoporosis [138].
Iridoid glycoside harpagoside, a major bioactive component of the
radix of Harpagophytum procumbens var. sublobatum (Engl.) Stapf
(Pedaliaceae), exhibits analgesic, anti-inﬂammatory, anti-phlogistic
and anti-osteoporotic eﬀects. Harpagoside treatment induces osteoblast
diﬀerentiation via upregulating the expression of β-catenin, cyclin D1
as well as c-Myc and downregulating Dkk1 expression [139]. in vitro
and in vivo experiments demonstrate that the AKT/GSK3/β-catenin axis
in osteosarcoma is probably inhibited by steroidal saponin dioscin, a
major compound of Liuwei Dihuang decoction and Di’ao Xinxue kang
[140].
As a derivative of coumarin, wedelolactone, isolated from Ecliptae
herba with the capability of nourishing bones, enhances osteo-
blastogenesis in mouse bone marrow mesenchymal stem cells through
enhancing β-catenin nuclear translocation and increasing levels of
phosphorylated GSK3β protein as well as runt-related transcription
factor 2 (Runx2) protein in the Wnt/GSK3β/β-catenin pathway [141].
Additionally, it is demonstrated that the terpenoids kirenol, astragalo-
side I and ﬂavone icariin have similar eﬀects on the Wnt/β-catenin
pathway and osteoblastic diﬀerentiation. Diterpenoid kirenol isolated
from Herba Siegesbeckiae promotes osteoblast diﬀerentiation in mouse
osteoid cell lines (MC3T3-E1) and accelerates the upregulation of LRP5,
disheveled2, Runx2, p-GSK3β as well as β-catenin in the Wnt/β-catenin
pathway, contributing to osteoblast diﬀerentiation [142]. Upregulated
expression of β-catenin and Runx2 has also been shown in MC3T3-E1
cells treated with Astragaloside I isolated from Astragalus membranaceus
[143], which possesses osteogenic properties and exhibits partially si-
milar eﬀects as icariin on the Wnt/β-catenin pathway with respect to
osteoblastic diﬀerentiation. Icariin is extracted from Epimedium brevi-
cornum Maxim, which promotes proliferation, diﬀerentiation and mi-
neralization of osteoblasts in MC3T3-E1 cells via enhancing nuclear
translocation of β-catenin and upregulating the mRNA and protein
expression of Runx2 [144]. Except for increased β-catenin and Runx2,
the expression of cyclin D1 and alkaline phosphatase is elevated in
icariin-treated osteoblastic cells from rat mandible [145]. In addition to
icariin, ﬂavone tricin, rich in rice bran or other grass species, enhances
osteoblastogenesis through upregulating Wnt3a expression while
downregulating GSK3β expression in human adult mesenchymal stem
cells [146]. Taken together, the Wnt/β-catenin pathway may be an
attractive therapeutic target of natural small molecules for the treat-
ment of bone disorders.
3.5. Other diseases
Rheumatoid arthritis is a chronic inﬂammatory illness that displays
painful swelling or inﬂammation of the synovial lining in the joints and
cartilage, as well as ultimate bone damage [147]. Mutations in CD28
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and CD40 or genetic variants of LRP5 in the Wnt/β-catenin pathway are
risk factors for bone damage in patients with rheumatoid arthritis
[148]. Both upregulated expression of Wnt5a or β-catenin play pro-
minent roles in the Wnt/β-catenin pathway in cultured ﬁbroblast-like
synoviocytes from rheumatoid arthritis patients [149]. Fortunately,
newly emerging anti-sclerostin therapies (romosozumab and bloso-
zumab) and several natural small molecules have shown a beneﬁcial
eﬀect on the treatment of rheumatoid arthritis through targeting the
Wnt/β-catenin pathway. Resveratrol, a natural polyphenolic compound
isolated from plants, has various physiological eﬀects, including anti-
cancer and anti-cardiovascular, and is expected to become a promising
natural product for clinical use, despite most related studies being
performed in animal models [150–153]. In collagen-induced arthritis
mice, levels of Wnt5a protein are decreased and the Wnt/β-catenin
pathway is suppressed by resveratrol [154]. Similar to resveratrol,
curcumin and epigallocat-echin-3-gallate isolated from green tea sup-
press arthritis and have an inhibitory eﬀect on the Wnt/β-catenin
pathway [155,156]. Intriguingly, as a metabolite of ginsenoside-Rb1,
ginsenoside F2 positively regulates the anagen phase and hair growth
through upregulating expression of β-catenin as well as LEF-1 and
downregulating expression of Dkk1 [157].
In addition, emerging studies have demonstrated that mutations in
Wnt/β-catenin signals are closely linked to multiple diseases, such as
synovial sarcoma, type II diabetes and myocardial ﬁbrosis. Aberrant
Wnt signaling and added β-catenin stabilization have been termed
secondary changes in synovial sarcoma, but eﬀective therapy for the
treatment of synovial sarcoma remains to be determined [158], en-
couraging further research to block synovial sarcoma tumour formation
by inhibiting the Wnt/β-catenin pathway. Mutations in Wnt5b and
transcription factor 7-like 2 are observed in type II diabetes [159].
Downregulated Wnt5a, FZD-related proteins and Dkk1 are discovered
in mutant pancreatic mesenchyme [160] and Wnt/β-catenin pathway is
activated in intervertebral disc cells [161], which is highly consistant
with previous ﬁndings. Additionally, overexpression of Wnt1 and
Wnt5a or the inhibitory activities of Wnt-C59 on Wnts are all evidence
of the critical role of the Wnt/β-catenin pathway in myocardial ﬁbrosis
progression and myoﬁbroblast formation [162]. Unfortunately, thus
far, no eﬀective natural small molecules have been applied to treat
these diseases that act through the Wnt/β-catenin pathway. Thereby,
these studies might provide a new avenue for natural small molecules
targeting the Wnt/β-catenin pathway in various diseases.
4. Concluding remarks
In summary, this systemic review examined the intervention of
natural small molecules on Wnt/β-catenin pathway with respect to
initiation and progression of cancers, renal diseases, neurodegenerative
diseases and bone disorders. Through elaborating on the mechanisms of
Wnt/β-catenin pathway using in vitro and in vivo experiments, further
insights into these mechanisms enable in-depth understanding of the
pathophysiology of those diseases and facilitate discovery of targeted
therapeutic agents.
After a pooled analysis of clinical and non-clinical natural products,
chemotherapeutic drugs and biological agents against the Wnt/β-ca-
tenin pathway, we learned that intracellular porcupine, extracellular
Wnt ligands as well as their receptors, and β-catenin-dependent pro-
teins, have become major targets of antagonists. Clinical trials have
shown that porcupine is a target of a novel inhibitor, ETC-159, with
poor oral bioavailability. Wnt3a is regarded as a target of microRNA-
15a-5p and microRNA-195 in colon cancer. LRP6 and FZD7/FZD8-Fc
are concurrently thought to be targets of sclerostin and nigericin.
Moreover, β-catenin expression is regulated by natural berberine and
sulphoraphane, while β-catenin-dependent proteins are targeted by
natural compounds, such as epigallocat-echin-3-gallate, triptonide, ur-
solic acid and toosendanin. In addition, interactions between β-catenin
and APC, TCF or CBP are inhibited by cercosporin, baicalein and ICG-
001, respectively. Unfortunately, with further research on antagonists,
a series of side eﬀects have been discovered, which severely restrict
their use. For example, R-Spondins inhibitor causes diﬀerentiation of
colon tumour cells and loss of stem cell function. Long-term users of the
GSK3 inhibitor lithium are diagnosed with a signiﬁcantly higher in-
cidence of renal cancers. As such, it is imperative to seek safe and ef-
fective targeted therapeutics to resolve the prominent problems that
continue to puzzle the biomedical community.
With the in-depth understanding of the mechanisms of aberrant
Wnt/β-catenin pathway in diseases, seeking targeted agents against
mutations in Wnt/β-catenin signals have drawn increasing attentions.
Of note, rich natural resources, together with advanced biotechnology,
have also oﬀered increasing possibilities for the development of novel
drugs and targeted agents. Excluding the natural small molecules
mentioned above (Table 1), natural rhein and baicalin, along with
natural terpenoids (timosaponin AIII, astragaloside IV, jatrophone and
4,10-aromadendranediol), have also been investigated and conﬁrmed
as promising compounds against the mutant Wnt/β-catenin pathway
(Fig. 3), which greatly inspires us to identify more targeted compounds
from nature. Notably, the generation of targeted natural small mole-
cules not only improves defects of existing therapeutic agents but also
provides opportunities for the treatment of diseases, such as the type II
diabetes, synovial sarcoma and myocardial ﬁbrosis.
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